Boston Scientific Corporation (NYSE:BSX) Vercise Gevia Deep Brain Stimulation (DBS) device has obtained a CE Mark approval in the European Union. The device is a rechargeable, magnetic resonance (MR) conditional system for treating movement disorder symptoms. Its use is mainly in patients with Parkinson’s disease, dystonia, and essential tremor.
This is not the first time Boston Scientific is bringing on board such a device. Five years ago the company introduced an eight-contact rechargeable platform with 25 years of longevity. Immediately after, the first directional lead powered by a small primary cell device hit the market.
DBS therapy involves stimulation of specific areas of the brain
The Vercise Gevia System has been put on target as the next generation rechargeable platform. It features the Neural Navigator 2 with STIMVIEW Technology, which will be handy in visualizing the stimulation field by physicians as they configure the Vercise Gevia. The system addresses the needs of both patients and physicians thanks to the latest advances in DBS therapy.
According to neurologist Professor Patricia Limousin who is also a neurologist, the Neural Navigator software is ideal for bringing together some of the most critical information physician needs to modify therapies for patients.
Her sentiments are echoed by Dr. Ludvic Zrinzo of London’s National Hospital for Neurology & Neurosurgery who notes, “With the Gevia system, patients benefit from directional stimulation within a rechargeable system while maintaining the ability to have an MRI. This flexibility in DBS therapy is a clear step forward for patients.”
Boston Scientific’s dedication in providing transformative technology
Typically, physicians have been relying primarily on patient feedback to complete their programming. Boston Scientific feels this is not perfect thus it intends to equip clinicians with transformative technology, which will help in improving the lives of patients. They will be better placed to define the settings using the directional DBS system that is also Full Body MRI Conditional.
Boston Scientific has been in the market for more than 35 years and its main goal has been to transform lives through innovative medical solutions. Parkinson’s disease is a progressive neurodegenerative disorder that affects nearly 10 million people worldwide. In the meantime, Boston Scientific’s stock was trading at $27.50 a fall of $0.01 or 0.04%
